HK Stock Market Move | YOURAN DAIRY (09858) closed up nearly 5%, the company plans to raise HK$2.3 billion in funds, which may drive future improvements in pasture integration.
Yuaran Pastoral (09858) surged nearly 5% by the end of trading, rising 4.84% to HK$4.98 as of the time of writing, with a trading volume of HK$108 million.
YOURAN DAIRY (09858) rose nearly 5% at the close of trading, rising 4.84% to HK$4.98 as of the time of drafting, with a turnover of HK$1.08 billion.
In terms of news, YOURAN DAIRY recently announced a share placement in a "old first, new later" manner, along with a special authorization for subscription, raising a total of approximately HK$2.33 billion, equivalent to about RMB 2.07 billion. The majority of this funding comes from its major shareholder Yili. After the transaction is completed, Yili's stake in YOURAN DAIRY will increase from 33.93% to 36.07%.
Cathay Haitong released a research report stating that the company's net proceeds from this fundraising are HK$2.33 billion, which will be used to repay loans and for digital transformation construction. The company will continue to drive cost reduction, efficiency improvement, and asset structure optimization. In addition, the acquisition of assets at the bottom of the cycle has a high cost-effectiveness, and the company may further integrate and optimize its ranch layout in the future.
Related Articles

GEELY AUTO (00175) announced on February 5th that it will spend 27.6459 million Hong Kong dollars to repurchase 171.8 million shares.

BINHAI INV (02886) bought back 10,000 shares at a cost of 11,200 Hong Kong dollars on 5 February.

Shanghai Fosun Pharmaceutical (02196): The application for a new indication for Fumain has been accepted for listing and included in the priority review program.
GEELY AUTO (00175) announced on February 5th that it will spend 27.6459 million Hong Kong dollars to repurchase 171.8 million shares.

BINHAI INV (02886) bought back 10,000 shares at a cost of 11,200 Hong Kong dollars on 5 February.

Shanghai Fosun Pharmaceutical (02196): The application for a new indication for Fumain has been accepted for listing and included in the priority review program.






